We reviewed

the long-term results of 41 treated super-morbid-obese patients. Mean initial BMI was 59.5 +/- 3.5 kg/m(2). Twelve patients (29.3 %) achieved after only LSG a BMI < 35 kg/m(2) (mean 31.9 +/- 2). They have lost 78.7 +/- 11.8 % of excess body weight (EBW). The remaining 28 patients lost 48.1 +/- 11.9 % of EBW and achieved a mean BMI of 44.2 +/- 4.3 kg/m(2), thus requiring the second stage. Ten of them (24.4 % of the total or 35.7 % of those in need), were submitted to laparoscopic Roux-en-Y gastric bypass (LRYGBP). They lost 71.9 +/- 4.3 % of EBW and have a mean BMI of 33.6 +/- 2.7 kg/m(2). The 18 remaining patients have a BMI of 42 +/- 3.6 kg/m(2) and they still suffer from morbid obesity. They have lost 48.5 +/- 8.7 % of EBW. The mean rate of EBW loss for all the available 39 patients LY2835219 inhibitor after either LSG or both LSG and LRYGBP has been 63.2 +/- 16.5 % after a mean follow-up of 42.8 +/- 19.5 months. Out of 41 patients, 1 died, 1 was lost to follow-up, 21 (51.2 %) achieved “”healthy”" BMIs and 18 (44 %) still require LRYGBP. The rate of cure of morbid obesity was 51.2 %. A remaining 44 % of super-morbid obese patients still need the completion LRYGBP but

have not undergone it. Half of these patients have lost > 50 % of their EBW. The two-stage strategy is an effective treatment plan for super-morbid obesity. A less patient-dependent strategy may be needed for a subset of patients.”
“Background: Clinical metabolomics is a recent “”omic”" technology which is defined as a global holistic overview of the personal metabolic status (fingerprinting). This technique allows to prove metabolic differences in different groups of people with Liproxstatin-1 the opportunity to explore interactions such as genotype-phenotype and genotype-environment type, whether normal or pathological. Aim: To study chronic kidney injury 1) using urine metabolomic profiles of young adults born extremely low-birth weight (ELBW) and 2) correlating a biomarker of kidney injury, urinary neutrophil gelatinase-associated lipocalin

selleck chemicals (NGAL), in order to confirm the metabolomic injury profile. Method: Urine samples were collected from a group of 18 people (mean: 24-year-old, std: 4.27) who were born with ELBW and a group of 13 who were born at term appropriate for gestational age (AGA) as control (mean 25-year-old, std: 5.15). Urine samples were analyzed by (1)H-nuclear magnetic resonance spectroscopy, and then submitted to unsupervised and supervised multivariate analysis. Urine NGAL (uNGAL) was measured using ARCHITECT (ABBOTT diagnostic NGAL kit). Results: With a multivariate approach and using a supervised analysis method, PLS-DA, (partial least squares discriminant analysis) we could correlate ELBW metabolic profiles with uNGAL concentration. Conversely, uNGAL could not be correlated to AGA. Conclusions: This study demonstrates the relevance of the metabolomic technique as a predictive tool of the metabolic status of exELBW.